Literature DB >> 23676463

Specific peripheral B cell tolerance defects in patients with multiple sclerosis.

Tuure Kinnunen1, Nicolas Chamberlain, Henner Morbach, Tineke Cantaert, Megan Lynch, Paula Preston-Hurlburt, Kevan C Herold, David A Hafler, Kevin C O'Connor, Eric Meffre.   

Abstract

Multiple sclerosis (MS) is a genetically mediated autoimmune disease of the central nervous system. B cells have recently emerged as major contributors to disease pathogenesis, but the mechanisms responsible for the loss of B cell tolerance in patients with MS are largely unknown. In healthy individuals, developing autoreactive B cells are removed from the repertoire at 2 tolerance checkpoints during early B cell development. Both of these central and peripheral B cell tolerance checkpoints are defective in patients with rheumatoid arthritis (RA) and type 1 diabetes (T1D). Here, we found that only the peripheral, but not the central, B cell tolerance checkpoint is defective in patients with MS. We show that this specific defect is accompanied by increased activation and homeostatic proliferation of mature naive B cells. Interestingly, all of these MS features parallel defects observed in FOXP3-deficient IPEX patients, who harbor nonfunctional Tregs. We demonstrate that in contrast to patients with RA or T1D, bone marrow central B cell selection in MS appears normal in most patients. In contrast, patients with MS suffer from a specific peripheral B cell tolerance defect that is potentially attributable to impaired Treg function and that leads to the accumulation of autoreactive B cell clones in their blood.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23676463      PMCID: PMC3668812          DOI: 10.1172/JCI68775

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Predominant autoantibody production by early human B cell precursors.

Authors:  Hedda Wardemann; Sergey Yurasov; Anne Schaefer; James W Young; Eric Meffre; Michel C Nussenzweig
Journal:  Science       Date:  2003-08-14       Impact factor: 47.728

Review 2.  Genomics and the multifactorial nature of human autoimmune disease.

Authors:  Judy H Cho; Peter K Gregersen
Journal:  N Engl J Med       Date:  2011-10-27       Impact factor: 91.245

Review 3.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 4.  B cells in multiple sclerosis: connecting the dots.

Authors:  H-Christian von Büdingen; Amit Bar-Or; Scott S Zamvil
Journal:  Curr Opin Immunol       Date:  2011-10-07       Impact factor: 7.486

5.  The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans.

Authors:  Laurence Menard; David Saadoun; Isabelle Isnardi; Yen-Shing Ng; Greta Meyers; Christopher Massad; Christina Price; Clara Abraham; Roja Motaghedi; Jane H Buckner; Peter K Gregersen; Eric Meffre
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

6.  Pervasive sharing of genetic effects in autoimmune disease.

Authors:  Chris Cotsapas; Benjamin F Voight; Elizabeth Rossin; Kasper Lage; Benjamin M Neale; Chris Wallace; Gonçalo R Abecasis; Jeffrey C Barrett; Timothy Behrens; Judy Cho; Philip L De Jager; James T Elder; Robert R Graham; Peter Gregersen; Lars Klareskog; Katherine A Siminovitch; David A van Heel; Cisca Wijmenga; Jane Worthington; John A Todd; David A Hafler; Stephen S Rich; Mark J Daly
Journal:  PLoS Genet       Date:  2011-08-10       Impact factor: 5.917

7.  Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells.

Authors:  Tuure Kinnunen; Nicolas Chamberlain; Henner Morbach; Jinyoung Choi; Sangtaek Kim; Joseph Craft; Lloyd Mayer; Caterina Cancrini; Laura Passerini; Rosa Bacchetta; Hans D Ochs; Troy R Torgerson; Eric Meffre
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

8.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

9.  Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy.

Authors:  Aisha V Sauer; Henner Morbach; Immacolata Brigida; Yen-Shing Ng; Alessandro Aiuti; Eric Meffre
Journal:  J Clin Invest       Date:  2012-05-24       Impact factor: 14.808

10.  Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors:  Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  75 in total

1.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 2.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

3.  Clonal analysis of B-cell response in pemphigus course: toward more effective therapies.

Authors:  Giovanni Di Zenzo; Giovanna Zambruno
Journal:  J Invest Dermatol       Date:  2015-03       Impact factor: 8.551

4.  Multiple sclerosis: defect in peripheral B-cell tolerance identified in MS.

Authors:  Katy Malpass
Journal:  Nat Rev Neurol       Date:  2013-06-04       Impact factor: 42.937

5.  Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Authors:  Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson
Journal:  Acta Neuropathol       Date:  2016-10-11       Impact factor: 17.088

Review 6.  Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.

Authors:  H-Christian von Büdingen; Arumugam Palanichamy; Klaus Lehmann-Horn; Brady A Michel; Scott S Zamvil
Journal:  Eur Neurol       Date:  2015-03-25       Impact factor: 1.710

7.  Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients.

Authors:  Erica L Eggers; Brady A Michel; Hao Wu; Sheng-Zhi Wang; Carolyn J Bevan; Aya Abounasr; Natalie S Pierson; Antje Bischof; Max Kazer; Elizabeth Leitner; Ariele L Greenfield; Stanislas Demuth; Michael R Wilson; Roland G Henry; Bruce Ac Cree; Stephen L Hauser; H-Christian von Büdingen
Journal:  JCI Insight       Date:  2017-11-16

8.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Authors:  Elizabeth Cotzomi; Panos Stathopoulos; Casey S Lee; Alanna M Ritchie; John N Soltys; Fabien R Delmotte; Tyler Oe; Joel Sng; Ruoyi Jiang; Anthony K Ma; Jason A Vander Heiden; Steven H Kleinstein; Michael Levy; Jeffrey L Bennett; Eric Meffre; Kevin C O'Connor
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

Review 9.  The Charcot Lecture | beating MS: a story of B cells, with twists and turns.

Authors:  Stephen L Hauser
Journal:  Mult Scler       Date:  2014-12-05       Impact factor: 6.312

10.  The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model.

Authors:  Xiangyang Zhang; Michael Ciesielski; Robert A Fenstermaker; Henry J Kaminski; Linda L Kusner
Journal:  J Immunol       Date:  2020-08-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.